Abstract 2729: Development of a targeted liquid biopsy for early gynecologic cancer detection leads to discovery of a highly prevalent genomic landscape of cancer driver gene mutations in uterine tissue from women without cancer

Author(s):  
Deep S. Pandya ◽  
Shannon Tomita ◽  
Olga Camacho ◽  
Sabina Swierczek ◽  
Catalina Camacho ◽  
...  
2019 ◽  
Vol 61 (1) ◽  
pp. 152-175 ◽  
Author(s):  
Kelly L. Harris ◽  
Meagan B. Myers ◽  
Karen L. McKim ◽  
Rosalie K. Elespuru ◽  
Barbara L. Parsons

Author(s):  
Shu-Hsuan Liu ◽  
Pei-Chun Shen ◽  
Chen-Yang Chen ◽  
An-Ni Hsu ◽  
Yi-Chun Cho ◽  
...  

Abstract An integrative multi-omics database is needed urgently, because focusing only on analysis of one-dimensional data falls far short of providing an understanding of cancer. Previously, we presented DriverDB, a cancer driver gene database that applies published bioinformatics algorithms to identify driver genes/mutations. The updated DriverDBv3 database (http://ngs.ym.edu.tw/driverdb) is designed to interpret cancer omics’ sophisticated information with concise data visualization. To offer diverse insights into molecular dysregulation/dysfunction events, we incorporated computational tools to define CNV and methylation drivers. Further, four new features, CNV, Methylation, Survival, and miRNA, allow users to explore the relations from two perspectives in the ‘Cancer’ and ‘Gene’ sections. The ‘Survival’ panel offers not only significant survival genes, but gene pairs synergistic effects determine. A fresh function, ‘Survival Analysis’ in ‘Customized-analysis,’ allows users to investigate the co-occurring events in user-defined gene(s) by mutation status or by expression in a specific patient group. Moreover, we redesigned the web interface and provided interactive figures to interpret cancer omics’ sophisticated information, and also constructed a Summary panel in the ‘Cancer’ and ‘Gene’ sections to visualize the features on multi-omics levels concisely. DriverDBv3 seeks to improve the study of integrative cancer omics data by identifying driver genes and contributes to cancer biology.


2013 ◽  
Vol 42 (D1) ◽  
pp. D1048-D1054 ◽  
Author(s):  
Wei-Chung Cheng ◽  
I-Fang Chung ◽  
Chen-Yang Chen ◽  
Hsing-Jen Sun ◽  
Jun-Jeng Fen ◽  
...  

Author(s):  
Jorge Francisco Cutigi ◽  
Renato Feijo Evangelista ◽  
Rodrigo Henrique Ramos ◽  
Cynthia de Oliveira Lage Ferreira ◽  
Adriane Feijo Evangelista ◽  
...  

2020 ◽  
Author(s):  
Zhenghao Liu ◽  
Meiguang Zheng ◽  
Bingxi Lei ◽  
Zhiwei Zhou ◽  
Yutao Huang ◽  
...  

Abstract Background: Lung cancer is the most aggressive cancer which representing one-quarter of all cancer-related deaths, and metastatic spread accounts for >70% of these deaths, especially brain metastasis. Metastasis associated mutations are important biomarkers for metastasis prediction and outcome improvement. Methods: In this study, we applied whole-exome sequencing to identify potential metastasis related mutation in 12 paired lung cancer and brain metastasis samples. Results: We identified 1,702 SNVs and 6,131 mutation events in 1,220 genes. Furthermore, we identified several lung cancer metastases associated genes (KMT2C, AHNAK2). A mean of 3.1 driver gene mutation events per tumor with the dN/dS of 2.13 indicating a significant enrichment for cancer driver gene mutations. Mutation spectrum analysis found lung-brain metastasis samples have more similar Ti/Tv(transition/transversion) profile with brain cancer in which C>T transitions are more frequently while lung cancer has more C>A transversion. We also found the most important tumor onset and metastasis pathways such as chronic myeloid leukemia, ErbB signaling pathway and glioma pathway. Finally, we identified a significant survival associated mutation gene ERF in both TCGA (P=0.01) and our dataset (P=0.012). Conclusion: In summary, we conducted a pairwise lung-brain metastasis based exome-wide sequencing and identified some novel metastasis related mutations which provided potential biomarkers for prognosis and targeted therapeutics.


Oncotarget ◽  
2016 ◽  
Vol 7 (38) ◽  
pp. 61054-61068 ◽  
Author(s):  
Jianmei Zhao ◽  
Xuecang Li ◽  
Qianlan Yao ◽  
Meng Li ◽  
Jian Zhang ◽  
...  

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Xiao-wei Du ◽  
Gao Li ◽  
Juan Liu ◽  
Chun-yan Zhang ◽  
Qiong Liu ◽  
...  

Abstract Background Breast cancer is the most common malignancy in women. Cancer driver gene-mediated alterations in the tumor microenvironment are critical factors affecting the biological behavior of breast cancer. The purpose of this study was to identify the expression characteristics and prognostic value of cancer driver genes in breast cancer. Methods The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets are used as the training and test sets. Classified according to cancer and paracancerous tissues, we identified differentially expressed cancer driver genes. We further screened prognosis-associated genes, and candidate genes were submitted for the construction of a risk signature. Functional enrichment analysis and transcriptional regulatory networks were performed to search for possible mechanisms by which cancer driver genes affect breast cancer prognosis. Results We identified more than 200 differentially expressed driver genes and 27 prognosis-related genes. High-risk group patients had a lower survival rate compared to the low-risk group (P<0.05), and risk signature showed high specificity and sensitivity in predicting the patient prognosis (AUC 0.790). Multivariate regression analysis suggested that risk scores can independently predict patient prognosis. Further, we found differences in PD-1 expression, immune score, and stromal score among different risk groups. Conclusion Our study confirms the critical prognosis role of cancer driver genes in breast cancer. The cancer driver gene risk signature may provide a novel biomarker for clinical treatment strategy and survival prediction of breast cancer.


Sign in / Sign up

Export Citation Format

Share Document